Navigation Links
Protege Encore Clinical Trial Evaluates New Investigational Approach For Individuals Recently Diagnosed With Type 1 Diabetes
Date:5/10/2010

WELLINGTON, Fla., May 10 /PRNewswire-USNewswire/ -- Dr. Richard Hays announced today that he is now recruiting children with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.

In patients with type 1 diabetes, T cells of the immune system attack and destroy beta cells that are located in the pancreas and make insulin. Teplizumab works by binding to CD3 receptors on the surface of the T cells and, by doing so, may modulate the autoimmune attack on pancreatic beta cells and preserve or protect these cells. If effective, patients may require less injected insulin and their blood glucose levels may be easier to control.

In an earlier trial of teplizumab, a small group of subjects with diabetes of recent onset were noted to have improved function of their beta cells, improved glucose control, and reduced insulin requirements for up to two years. These findings are being further studied in the Protege and Protege Encore clinical trials.

The Protege Encore trial is designed to determine if teplizumab can preserve pancreatic insulin production, which may make diabetes easier to manage. "We have a lot of enthusiasm about the teplizumab studies and their implications. It is hoped that one day we can offer a new treatment option to help patients better manage their disease," Dr. Hays commented.

Approximately 125 study sites across 16 countries will be enrolling 400
'/>"/>

SOURCE Richard M. Hays, M.D., P.A.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
2. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
3. Novocell Becomes ViaCyte, Inc., as it Accelerates Pre-Clinical Development of a Stem Cell Derived Treatment for Diabetes
4. Stereotaxis Updates Progress on Major Clinical Initiative Related to Electrophysiology (EP) Treatment of Ventricular Tachycardia
5. US HIFU Receives Unanimous Approval to Continue the Clinical Investigation of High Intensity Focused Ultrasound (HIFU) for Treatment of Prostate Cancer
6. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2010 Financial Results
7. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
8. US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting Drugs of Tomorrow
9. OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Demonstrates Excellent Safety and Clinical Outcomes in High-Risk Elderly Patients
10. Lotus Pharmaceuticals Laevo-Bambuterol Received SFDA Approval to Commence Clinical Trials
11. Novavaxs Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , July 1, 2015 Precyse, a ... education, announced today that, as part of its long ... agreement to be acquired by investment firm Pamplona Capital ... equity investors, Altaris Capital Partners and NewSpring Capital, have ... 1999, has assisted nearly 5,000 healthcare facilities and systems ...
(Date:7/1/2015)... July 1, 2015  Echo Therapeutics, Inc. (NASDAQ: ... on non-invasive continuous glucose monitoring and associated technologies, ... completely re-designed corporate website echotx.com . Echo,s ... Echo,s technology and enhances the quality and availability ... better communicates to prospective customers and stakeholders what ...
(Date:7/1/2015)... FT LAUDERDALE, Florida , July 1, 2015 /PRNewswire/ ... manufacturer and marketer of innovative medical devices for the treatment ... it prevailed in a final opposition appeal hearing in the ... 482 - STENT HAVING HELICAL ELEMENTS (,482). The ,482 patent ... and has been upheld as a valid patent in amended ...
Breaking Medicine Technology:Precyse Enters into Acquisition Agreement with Pamplona Capital Management 2Precyse Enters into Acquisition Agreement with Pamplona Capital Management 3Echo Therapeutics Announces New Website Launch 2Echo Therapeutics Announces New Website Launch 3OrbusNeich Announces Favorable Ruling from the European Patent Office and Initiation of Litigation Against Terumo Corporation 2
... 2011 United Seating & Mobility (USM) is ... with Central Kentucky Mobility (CKM) to acquire and merge its ... Lexington, Louisville, as well as central, eastern and southern Kentucky. ... strengthens our position within a core market for us and ...
... users from Europe, Asia, the Middle East, North America ... Germany June 16-19 to participate in Elekta,s fifth European ... presentations and workshops given by Elekta users and company ... The Users, Conference was preceded by the Elekta Stereotactic ...
Cached Medicine Technology:Elekta European Users' Conference Attracts Top Minds in Cancer Management 2Elekta European Users' Conference Attracts Top Minds in Cancer Management 3
(Date:7/1/2015)... NY (PRWEB) , ... July 01, 2015 , ... The ... from the New York Community Trust. The grant will allow CCF to improve quality ... proven practices. , CCF was formed to respond to many changes in New York’s ...
(Date:7/1/2015)... ... 2015 , ... Did you know that infertility in men is more common ... Advanced Fertility Center of Texas (AFCT) would like to talk about some natural ways ... considered to be a “woman’s issue,” male fertility factors can play a role in ...
(Date:7/1/2015)... ... July 01, 2015 , ... “Well-meaning social policy ... a Professor in FIU’s School of International and Public Affairs. , ... participated in the National Survey on Drug Use and Health, which is a ...
(Date:7/1/2015)... ... ... Franklin University, one of the leading educators of working adults in central ... of the College of Health & Public Administration . , In ... mission of Franklin University via curriculum planning, course scheduling, faculty staffing and development, and ...
(Date:7/1/2015)... ... ... Author Francesca Camp wasn’t always a steadfast supporter of plastic surgery. But just ... of the practice; a terrible car accident years ago left her injured and in need ... It ? (And What if I Do?): Answers to All Your Questions about Plastic Surgery” ...
Breaking Medicine News(10 mins):Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 2Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 4Health News:Researchers find that medical marijuana laws increase recreational marijuana use among juveniles 2Health News:Franklin University Appoints Dean of College of Health & Public Administration 2Health News:Francesca Camp’s New Book Unmasks Plastic Surgery Advice 2
... Some skin cancers, in particular basal cell ... containing the compound imiquimod. The antitumor effect of imiquimod ... imiquimod,s antitumor effects is its ability to modify the ... Sibilia, at the Medical University of Vienna, Austria, has ...
... in pharmaceutical drugs can obviously save lives. But as more ... the broader health impact of all these chemicals has not ... exceptionally little information on how chemicals in our drugs and ... we eat, impact some of the most important cells in ...
... the first time ever, stem cells from umbilical cords have ... lead to new treatment options for spinal cord injuries and ... "This is the first time this has been done ... Central Florida bioengineer and leader of the research group, whose ...
... rap in past research studies, being labeled the group ... But a researcher from the Mandel School of Applied ... findings in a new studydemonstrating that inmates with severe ... than those with substance abuse issues or no mental ...
... Kathleen Doheny HealthDay Reporter , TUESDAY, Jan. ... an aggressive type of breast cancer known as HER2-positive ... researchers report. The dual-drug approach greatly boosted the ... the time a woman was due to have surgery, ...
... the Centro de Genmica e Investigacin Oncolgica (GENYO) of ... Regional Government are members have identified the genetic and ... process of metastasis -which is the main cause of ... organs with no direct anatomical relationship with the organ ...
Cached Medicine News:Health News:JCI online early table of contents: Jan. 17, 2012 2Health News:JCI online early table of contents: Jan. 17, 2012 3Health News:JCI online early table of contents: Jan. 17, 2012 4Health News:Researchers study how chemicals in drugs and around us impact stem cells 2Health News:Researchers study how chemicals in drugs and around us impact stem cells 3Health News:A first: Brain support cells from umbilical cord stem cells 2Health News:A first: Brain support cells from umbilical cord stem cells 3Health News:Mental illness protects some inmates from returning to jail 2Health News:Drug Duo May Help Fight Aggressive Form of Breast Cancer 2Health News:Drug Duo May Help Fight Aggressive Form of Breast Cancer 3Health News:University of Granada researchers identify changes in tumor cells that lead to metastasis 2
... Accutome Ultrasound Advent Pachymeter exceeds previous product ... ALK and other lamellar procedures, the measurement ... microns. High end range is 1000 microns ... care. Newly designed 55 angle probe ensures ...
Precision that fits in the palm of your hand and measures down to 125 microns, the Pocket Pachymeter is about 8" X 4" x 2" and really does fit in a lab coat pocket or briefcase....
15 segment Vertical Prism Bar provides 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 25, 30 PD (Note: 30 PD is on the bar). 4447 xx Vertical Prism Bar....
Valleylab Surgistat II generator provides exceptional performance, reliability, and safety benefits in a compact, easy to use unit....
Medicine Products: